Because market access strategies should be rooted in the truth, not conjecture

We allow biopharma to ask the right people the right questions at the right time

Formulary Insights helps biopharma manufacturers and investors navigate the US market access landscape.

Clients leverage the combined expertise of our team and our panel to maximize investments with BD&L, pipeline development and inline products.”

NO RETIREES, NO LOOSE AFFILIATIONS, NO MISREPRESENTATIONS

All our panelists are active decision makers

Business Meeting
Syndicated-Research-Sample_edited.jpg

Click here for a Formulary Insights one-pager you can socialize with your teammates.

TESTIMONIALS

Pre-launch Study Evaluations gave us the insights that informed Phase 3 study design in time for us to include critical payer endpoints.
With a second indication on the horizon, a therapeutic class Drug Monograph Analysis revealed several unexpected perspectives that we leveraged to protect access.
Pre-launch competitive Label Comparison enabled us to prioritize our label negotiations to ensure our payer value was well represented at launch.
When we launched our small KAM team, we targeted Hospital System panelists to garner system-specific product insights that drove segmentation and prioritization of KAM targeting.
We bought a Rapid Study subscription so that we can put out fires quickly based on feedback from our panelists whenever we need it!
A Formulary Insights Direct Inquiry provided us with the payer insights we needed to make a go or no-go decision on several planned product strategies based on their expected access impact, quickly enhancing our product access and performance.

HOW WE ARE BETTER

HOW WE ARE BETTER

OUR PEOPLE
Experienced market access experts at your side from start-to-finish
OUR PANEL
Only active market access
experts… no retirees, no
loose affiliations
OUR APPROACH
Agile research unleashes
progressive learning and
more actionable insights
OUR PEOPLE
Experienced market access experts at your side from start-to-finish
OUR PANEL
Only active market access experts… no retirees, no loose affiliations